ak 2123 has been researched along with Experimental Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Konovalova, NP | 1 |
| Cherdyntseva, NV; Choinzonov, EL; Kagiya, TV; Kondakova, IV; Tcheredova, VV; Zagrebelnaya, GV | 1 |
2 other study(ies) available for ak 2123 and Experimental Neoplasms
| Article | Year |
|---|---|
Ultralow doses of various drugs in chemotherapy of experimental tumors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Indazoles; Leukemia P388; Lung Neoplasms; Melanoma; Mice; Mitomycin; Neoplasm Metastasis; Neoplasms, Experimental; Triazoles; Xenograft Model Antitumor Assays | 2003 |
Production of nitric oxide by hypoxic radiosensitizer sanazole.
Topics: Animals; Cell Hypoxia; Lymphoma; Mastocytoma; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; Nitric Oxide; Oxyhemoglobins; Radiation-Sensitizing Agents; Triazoles | 2004 |